GENEVA and AMSTERDAM, March 20, 2025 /PRNewswire/ — iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye.
Melanoma News
New potential nanocarrier cancer vaccine could rescue immune response against melanoma
Researchers have created a new vaccine for the treatment of late-stage metastatic melanoma, an aggressive skin cancer that can resist conventional treatments because it exists in an ecosystem that suppresses the body’s immune response.
Beating the clock: Melanoma starts evading treatment within hours — here’s how to stop it
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
The Promise of OBX-115, a Novel TIL Therapy, in Melanoma
Cancer treatment vaccines have been in development since 2010, when the first was approved for prostate cancer, followed by another in 2015 for melanoma. While many therapeutic (rather than preventive) cancer vaccines have been researched since then, none have received approval. A major challenge in their development is identifying tumor antigens that are distinct enough from normal cells to trigger a strong immune response.